AAPL 188.99 -0.13 (-0.07%)MSFT 128.09 -0.03 (-0.02%)FB 185.32 +0.01 (+0.01%)ZNGA 6.19 -0.01 (-0.16%)NVDA 156.55 +0.3 (+0.19%)WBA 52.27 -0.05 (-0.09%)GOOG 1161.8 -0.53 (-0.05%)PIH 5.82 +0.25 (+4.49%)
AAPL 188.99 -0.13 (-0.07%)MSFT 128.09 -0.03 (-0.02%)FB 185.32 +0.01 (+0.01%)ZNGA 6.19 -0.01 (-0.16%)NVDA 156.55 +0.3 (+0.19%)WBA 52.27 -0.05 (-0.09%)GOOG 1161.8 -0.53 (-0.05%)PIH 5.82 +0.25 (+4.49%)

Financial Summary KALV Quote KalVista Ph

KalVista Pharmaceuticals Inc. Quote

KalVista Pharma (KALV)

23.89 0.04 Healthcare
Stock Performance rating :
Recommendation :
Strong Sell
Score :
C-
Symbol KALV
Price 23.89
Beta 2.44
Vol Avg 33.84 K
Mkt cap 451.36 M
Shares 1
Last Div Not Available
Div Yield 0.00%
DCF Unlevered 0.00
DCF Levered 0.00
ROE 59.46% Strong Buy
ROA -88.00% Strong Sell
Operating Margin -750.00% Strong Sell
Debt/Equity -167.57% Sell
P/E -2.17 Sell
P/B -0.65
All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Income Statement
Year 20142015201620172018
Revenue 2 0 2 0 0
COGS 0 0 0 0 0
GrossProfit 2 0 2 2 8
Depreciation (included in COGS) 0 0 0 0 0
StockBasedCompe (included in COGS) 0 1 0 0 1
ResearchAndDeve 8 16 15 13 18
SalesGeneralAnd 2 5 3 11 9
OperatingIncome -8 -21 -15 -22 -19
InterestExpense 0 1 0 0 0
OtherIncome 1 -3 4 4 3
IncomeBeforeTax -7 -25 -11 -19 -16
ProvisionForInc 0 0 0 0 0
NetIncome -7 -25 -11 -19 -16
Balance Sheet
Year 20142015201620172018
CashAndCashEqui 4 54 22 31 51
ShortTermInvest 0 0 0 0 0
Cash 4 54 22 0 0
AccountReceivab 0 0 2 0 0
Inventories 0 0 0 0 0
DeferredIncomeT 0 0 0 0 0
OtherCurrentAss 0 0 0 0 0
TotalCurrentAss 5 55 25 34 59
PPE 1 1 0 0 2
AccumulatedDepr 0 -1 0 0 -1
NetPPE 0 1 0 0 2
EquityAndOtherI 0 0 0 0 0
Goodwill 0 0 0 0 0
IntangibleAsset 0 0 0 0 0
OtherLTAssets 2 1 0 0 0
TotalNonCurrent 2 2 0 0 2
TotalAssets 7 57 25 34 61
ShortTermDebt 4 1 0 0 0
AccountsPayable 1 1 1 0 0
TaxesPayable 0 0 0 0 0
AccruedLiabilit 2 1 1 0 0
DeferredRevenue 0 0 0 0 18
OtherCurrentLia 0 0 1 1 1
TotalCurrentLia 7 4 3 3 23
Debt 2 3 0 0 0
DeferredTaxesLi 0 0 0 0 0
DeferredRevenue 0 0 0 0 0
OtherLTLiabilit 42 0 59 0 11
TotalNonCurrent 44 3 59 0 11
TotalLiabilitie 51 7 62 3 34
CommonStock 0 0 0 0 0
AdditionalPaidI 4 122 0 90 100
RetainedEarning -48 -73 -37 -56 -72
AccumulatedOthe 0 0 0 -3 -1
TotalStockholde -44 49 -37 31 27
TotalLiabilitie 7 57 25 34 61
Cash Flow Statement
Year 20142015201620172018
NetIncome -7 -25 -11 -19 -16
Depreciation 0 0 0 0 0
DeferredIncomeT 0 0 0 0 0
StockBasedCompe 0 1 0 0 1
AccountsReceiva 0 0 0 0 0
InventoryCS 0 0 0 0 0
AccountsPayable 0 0 0 -2 0
OtherWorkingCap 0 0 -1 -1 25
OtherNonCashIte 0 4 -2 -1 -1
NetCashProvided -6 -21 -13 -24 11
InvestmentsInPP 0 -1 0 0 -1
AcquisitionsNet 0 0 0 0 0
PurchasesOfInve 0 0 0 0 0
SalesMaturities 0 0 0 0 0
PurchasesOfInta 0 0 0 0 0
OtherInvestingA 0 0 0 34 0
NetCashUsedForI 0 -1 0 34 -1
DebtIssued 0 4 0 0 0
DebtRepayment 0 0 0 0 0
CommonStockIssu 0 68 0 0 9
CommonStockRepu 0 0 0 0 0
DividendPaid 0 0 0 0 0
OtherFinancingA 0 0 0 0 0
NetCashProvided 9 72 33 0 9
NetChangeInCash 2 50 19 9 20
CashAtBeginning 0 4 3 22 31
CashAtEndOfPeri 3 54 22 31 51
Retained Earnings
Year 20142015201620172018
RetainedEarning ----48-73
NetIncome ---7-25-11
StockDividend --5550-25
DividendPaid -----
RetainedEarning ---48-73-37
Property Plant and Equipment Schedule
Year 20142015201620172018
NetPPE ----1
DeprAnnual 0---11
CapitalExpendit 00010
NetPPE ---1-
Intangible and Goodwill Schedule
Year 20142015201620172018
intAndGW 0----
Amortization 0--1-1
NewPurchases 0---11
intAndGW -----
Company Profile

CEO

Thomas Andrew Crockett

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ Global Market

Description

KalVista Pharmaceuticals Inc is a pharmaceuticals company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases.